Elevated ADH5 expression suggested better prognosis in kidney renal clear cell carcinoma (KIRC) and related to immunity through single-cell and bulk RNA-sequencing

Background Despite the rapid advances in modern medical technology, kidney renal clear cell carcinoma (KIRC) remains a challenging clinical problem in urology.

Researchers urgently search for useful markers to break through the therapeutic conundrum due to its high lethality.

Therefore, the study explores the value of ADH5 on overall survival (OS) and the immunology of KIRC.

Methods The gene expression matrix and clinical information on ADH5 in the TCGA database were validated using external databases and qRT-PCR.

To confirm the correlation between ADH5 and KIRC prognosis, univariate/multivariate Cox regression analysis was used.

We also explored the signaling pathways associated with ADH5 in KIRC and investigated its association with immunity.

Results The mRNA and protein levels showed an apparent downregulation of ADH5 in KIRC.

Correlation analysis revealed that ADH5 was directly related to histological grade, clinical stage, and TMN stage ( p  < 0.05).

Univariate and multivariate Cox regression analysis identified ADH5 as an independent factor affecting the prognosis of KIRC.

Enrichment analysis looked into five ADH5-related signaling pathways.

The results showed no correlation between ADH5 and TMB, TNB, and MSI.

From an immunological perspective, ADH5 was found to be associated with the tumor microenvironment, immune cell infiltration, and immune checkpoints.

Lower ADH5 expression was associated with greater responsiveness to immunotherapy.

Single-cell sequencing revealed that ADH5 is highly expressed in immune cells.

Conclusion ADH5 could be a promising prognostic biomarker and a potential therapeutic target for KIRC.

Besides, it was found that KIRC patients with low ADH5 expression were more sensitive to immunotherapy.